Study Stopped
Difficulty with recruitment in this patient population.
Diagnostic Performance of Coronary CT Angiography With CT FFR in Kidney Transplantation Candidates
1 other identifier
observational
26
1 country
1
Brief Summary
Patients with chronic kidney disease (CKD) before kidney transplantation require that obstructive coronary artery disease (CAD) is excluded, as cardiovascular complications are the leading cause of mortality in kidney transplant patients. However, in this patient population, the optimal method for the detection of obstructive CAD has not been identified. Noninvasive stress tests such as Dobutamine stress echocardiography or nuclear perfusion study have low diagnostic accuracy. CT fractional flow reserve measurement (CT FFR) is a novel non-invasive (FDA approved) imaging test to identify obstructive CAD. The goal of this project is to evaluate the diagnostic accuracy of CT FFR in the detection of obstructive coronary artery disease in patients with chronic kidney disease before kidney transplantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 10, 2017
CompletedFirst Posted
Study publicly available on registry
August 14, 2017
CompletedStudy Start
First participant enrolled
August 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 24, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 24, 2020
CompletedJanuary 6, 2022
December 1, 2021
2.4 years
August 10, 2017
December 16, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Diagnostic accuracy of CT FFR.
Diagnostic accuracy of CT FFR (per vessel) in the detection of hemodynamically significant CAD as compared to invasive FFR derived from invasive coronary angiography (reference standard). Presence or absence of hemodynamically significant coronary artery disease in concordance between CT FFR and invasive FFR. Hemodynamically significant stenosis is defined as CT FFR value below 0.8.
CT FFR and Invasive FFR are calculated immediately after coronary CT angiography and invasive coronary angiography
Interventions
CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
Eligibility Criteria
Candidates for kidney transplantation without any residual kidney function and referred to cardiac evaulation.
You may qualify if:
- Candidates for kidney transplantation on dialysis without any residual kidney function AND referred to invasive coronary angiography for cardiac evaluation
- Referral to invasive coronary angiography is based on algorithm used at the Transplant Readiness Assessment Clinic (TRAC) at Stanford:
- A. Diabetic Candidates older than 45 years.
- B. Diabetic Candidates under 45 years old and any one of the following criteria is present:
- a) 25 year History of Diabetes
- b) 5 year Smoking History
- c) Abnormal EKG (ST-T wave changes)
You may not qualify if:
- Hemodynamically and clinically unstable condition (angina at rest, malignant arrhythmias)
- Known ischemic heart disease (prior, documented myocardial infarction, prior stenting or coronary artery bypass graft surgery)
- BMI\>30 kg/m2, or weight \>120 kg.
- Atrial fibrillation or other arrhythmia, \>6 ectopic beats per minute
- Known or suspected allergy to iodinated contrast medium
- Pregnancy cannot be excluded
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Stanford Universitylead
- Siemens Medical Solutionscollaborator
Study Sites (1)
Stanford Healthcare
Stanford, California, 94305, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dominik Fleischmann, M.D.
Stanford Radiology
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Radiology
Study Record Dates
First Submitted
August 10, 2017
First Posted
August 14, 2017
Study Start
August 28, 2017
Primary Completion
January 24, 2020
Study Completion
January 24, 2020
Last Updated
January 6, 2022
Record last verified: 2021-12
Data Sharing
- IPD Sharing
- Will not share